Clal Biotechnology Industries (XTAE:CBI) EPS (Basic): ₪-0.09 (TTM As of Dec. 2025)


XTAE:CBI Clal Biotechnology Industries Ltd XTAE:CBI
23 GF Score
Price ₪0.27
GF Value ₪0.38
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Clal Biotechnology Industries EPS (Basic)?

Clal Biotechnology Industries XTAE:CBI 23 EPS (Basic) is ₪-0.09 as of Dec. 2025. GuruFocus rates XTAE:CBI with a GF Score™ of 23/100 and a GF Value™ of ₪0.38 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Clal Biotechnology Industries's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was ₪-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-0.09.

Clal Biotechnology Industries's EPS (Diluted) for the six months ended in Dec. 2025 was ₪-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-0.09.

Clal Biotechnology Industries's EPS without NRI for the six months ended in Dec. 2025 was ₪-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.07.

During the past 3 years, the average EPS without NRI Growth Rate was 32.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Clal Biotechnology Industries's highest 3-Year average EPS without NRI Growth Rate was 54.50% per year. The lowest was -43.90% per year. And the median was 17.70% per year.

Clal Biotechnology Industries  (XTAE:CBI) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Clal Biotechnology Industries EPS (Basic) Related Terms

Clal Biotechnology Industries EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Clal Biotechnology Industries's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clal Biotechnology Industries EPS (Basic) Chart

Clal Biotechnology Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.57 -0.39 -0.20 -0.40 -0.09

Clal Biotechnology Industries Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.26 -0.14 -0.07 -0.02
XTAE:CBI
23GF Score
Clal Biotechnology Industries Ltd XTAE:CBI
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clal Biotechnology Industries EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Clal Biotechnology Industries's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-13.319-0)/156.846
=-0.08

Clal Biotechnology Industries's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.969-0)/165.835
=-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₪-0.09 mean?
Clal Biotechnology Industries (XTAE:CBI) has a EPS (Basic) of ₪-0.09 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clal Biotechnology Industries and its competitors.
Is Clal Biotechnology Industries' EPS (Basic) too high?
Clal Biotechnology Industries' current EPS (Basic) is ₪-0.09. Overall, Clal Biotechnology Industries has a GF Score™ of 23/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clal Biotechnology Industries' EPS (Basic) compare to VRTX and REGN?
Clal Biotechnology Industries' EPS (Basic) of ₪-0.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Clal Biotechnology Industries and its competitors. Clal Biotechnology Industries's current EPS (Basic) is ₪-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Biotechnology Industries stock overvalued right now?
Based on GuruFocus' analysis, Clal Biotechnology Industries (XTAE:CBI) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪0.38, compared to a current price of ₪0.27 — trading 28.4% below its estimated fair value. The current EPS (Basic) is ₪-0.09. Clal Biotechnology Industries' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Clal Biotechnology Industries (XTAE:CBI), the current EPS (Basic) is ₪-0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clal Biotechnology Industries (XTAE:CBI) Overvalued in 2026?

Based on GuruFocus' analysis, Clal Biotechnology Industries stock appears to be undervalued. The current stock price of ₪0.27 is trading 28.4% below its estimated GF Value™ of ₪0.38. GuruFocus considers Clal Biotechnology Industries to be Modestly Undervalued.

Key valuation signals for XTAE:CBI:

  • EPS (Basic): ₪-0.09
  • GF Value™: ₪0.38 vs. price of ₪0.27 (28.4% below fair value)
  • GF Score™: 23/100 with 3 warning signs

No single metric tells the full story. See the XTAE:CBI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clal Biotechnology Industries Business Description

Address Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
23GF Score

Get the complete analysis for XTAE:CBI

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.27
Price
₪0.38
GF Value